Patents by Inventor Itay Levin
Itay Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092888Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: ApplicationFiled: October 23, 2023Publication date: March 21, 2024Applicant: Aulos Bioscience, IncInventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
-
Publication number: 20240059769Abstract: Described herein are engineered dual binding antibodies that bind to IL-13 and TSLP and uses thereof. Uses include treating allergic and respiratory conditions. Described herein are also libraries comprising the engineered dual binding antibodies, and methods of producing the engineered dual binding antibodies and functional and biochemical characterization of the antibodies.Type: ApplicationFiled: September 27, 2023Publication date: February 22, 2024Applicant: Biolojic Design Ltd.Inventors: ALIK DEMISHTEIN, Shmuel BERNSTEIN, Tomer SHLAMKOVICH, Ayelet CHEN, Yehezkel SASSON, Marek STRAJBL, Itay LEVIN, Sharon FISCHMAN, Yanay OFRAN, Guy NIMROD, Alexey SHNYDER, Hadar GATTEGNO, Nikol MALCHENKO, Olga BLUVSHTEIN YERMOLAEV, Noam GROSSMAN, Liron DANIELPUR, Itzhak MEIR, Morya IFRACH, Reut BARAK FUCHS, Michael ZHENIN
-
Patent number: 11851485Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: GrantFiled: November 16, 2022Date of Patent: December 26, 2023Assignee: AULOS BIOSCIENCE, INC.Inventors: Inbar Amit, Itay Levin, Guy Nimrod, Sharon Fischman, Reut Barak Fuchs, Marek Strajbl, Timothy Wyant, Michael Zhenin, Olga Bluvshtein Yermolaev, Yehezkel Sasson, Noam Grossman, Natalia Levitin, Yanay Ofran
-
Publication number: 20230203152Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: ApplicationFiled: November 16, 2022Publication date: June 29, 2023Applicant: Aulos Bioscience, IncInventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
-
Publication number: 20230167188Abstract: The present disclosure describes a number of anti-TNFR2 (tumor necrosis factor receptor 2) antibodies. These antibodies are TNFR2 agonists. In certain cases, these antibodies agonize TNFR2 in an Fc independent manner. These antibodies can modulate the proliferation and/or functions of regulatory T cells and myeloid-derived suppressor cells. In certain instances, these antibodies can be used to treat diseases such as GvHD or autoimmune diseases.Type: ApplicationFiled: July 1, 2021Publication date: June 1, 2023Applicant: Biolojic Design Ltd.Inventors: Inbar AMIT, Itay LEVIN, Ayelet CHEN, Tal VANA, Nino OREN, Dor SAMET, Efrat CHOEN ZADA, Natalia LEVITIN, Guy NIMROD, Yehezkel SASSON, Alik DEMISHTEIN, Timothy WYANT, Reut BARAK FUCHS, Yair FASTMAN, Sharon FISCHMAN, Marek STRAJBL, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Noam GROSSMAN, Oshrat Shir TWITO, Nevet Zur BITON, Liron DANIELPUR, May Sofia BEN MAYOR, Yanay OFRAN
-
Publication number: 20230085471Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.Type: ApplicationFiled: February 15, 2021Publication date: March 16, 2023Applicant: Aulos Bioscience, IncInventors: Inbar AMIT, Itay LEVIN, Guy NIMROD, Sharon FISCHMAN, Reut BARAK FUCHS, Marek STRAJBL, Timothy WYANT, Michael ZHENIN, Olga BLUVSHTEIN YERMOLAEV, Yehezkel SASSON, Noam GROSSMAN, Natalia LEVITIN, Yanay OFRAN
-
Patent number: 10394429Abstract: Example embodiments relate to sharing of user interface objects via a shared space in a data sharing application. In example embodiments, a data sharing application provides a shared space. A user command may then be received to transfer a respective UI object from each of a plurality of applications to the shared space. In response, each transferred UI object may be displayed within the shared space, such that each displayed UI object retains associated functionality from the corresponding application within the shared space. Finally, each UI object in the shared space may be shared with a plurality of users granted access to the shared space.Type: GrantFiled: June 29, 2012Date of Patent: August 27, 2019Assignee: QUALCOMM IncorporatedInventors: Benjamin Andrew Rottler, Pilar Ariella Strutin-Belinoff, Lindsay J Metcalfe, Itai Vonshak, Velma Velazquez, Chadwyck Wirtz, Suresh Arumugam, Greg Arroyo, Itay Levin, Alex Rapoport
-
Patent number: 10308703Abstract: Death-domain receptor 3 (DR3) variants having increased binding affinity to TL1A, and composition comprising same, are provided. Further, methods of use of said peptides or composition, including, but not limited to treatment of autoimmune and/or inflammatory disease are provided.Type: GrantFiled: April 27, 2015Date of Patent: June 4, 2019Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IInventors: Amir Aharoni, Itay Levin
-
Publication number: 20170114118Abstract: Death-domain receptor 3 (DR3) variants having increased binding affinity to TL1A, and composition comprising same, are provided. Further, methods of use of said peptides or composition, including, but not limited to treatment of autoimmune and/or inflammatory disease are provided.Type: ApplicationFiled: April 27, 2015Publication date: April 27, 2017Inventors: Amir AHARONI, Itay LEVIN
-
Publication number: 20160334967Abstract: Example embodiments relate to sharing of user interface objects via a shared space in a data sharing application. In example embodiments, a data sharing application provides a shared space. A user command may then be received to transfer a respective UI object from each of a plurality of applications to the shared space. In response, each transferred UI object may be displayed within the shared space, such that each displayed UI object retains associated functionality from the corresponding application within the shared space. Finally, each UI object in the shared space may be shared with a plurality of users granted access to the shared space.Type: ApplicationFiled: June 29, 2012Publication date: November 17, 2016Applicant: QUALCOMM IncorporatedInventors: Benjamin Rottler, Pilar Strutin-Belinoff, Lindsay J. Metcalfe, Itai Vonshak, Velma Velazquez, Chadwyck Wirtz, Suresh Arumugam, Greg Arroyo, Itay Levin, Alex Rapoport